Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 57-65 , March 2007

Treatment of relapsed or refractory acute promyelocytic leukemia

  • Martin S. Tallman (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationTel.: +1 312 695 6180; Fax: +1 312 695 6189.

References 

  1. Lo Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation: Results of the AIDA-2000 trial of the Italian GIMEMA Group. Blood. 2004;104:115a;(abstract 392)
  2. Miyawaki S, Sakamaki H, Ohtake S, et al. Postremission therapy in adult acute myeloid leukemia (AML): a randomized comparison of intensified consolidation therapy without maintenance therapy against conventional consolidation with maintenance therapy – JALSG AML-97 trial. Blood. 2004;104:248a;(abstract)
  3. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999;94:1192–1200
  4. Lengfelder E, Reichert A, Schoch C, et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia. 2000;14:1362–1370
  5. Tallman MS, Nabhan C, Feusner JH, et al. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99:759–767
  6. Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103:1237–1243
  7. Fujisawa S, Kanamori H, Tanaka M, et al. Relapse of acute promyelocytic leukemia after 10 years long-term remission. Leukemia & Lymphoma. 2002;43:679–680
  8. Specchia G, Lo CF, Vignetti M, et al. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. Journal of Clinical Oncology. 2001;19:4023–4028
  9. Latagliata R, Breccia M, Carmosino I, et al. Late relapse (>5 years from diagnosis) in acute promyelocytic leukemia (acute promyelocytic leukemia). Haematologica Reports. 2005;1:53;(abstract P39)
  10. Murray CK, Estey E, Paietta E, et al. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?. Journal of Clinical Oncology. 1999;17:293–297
  11. Montesinos P, De La Serna J, Vellenga E, et al. Clinical features and outcome of patients with acute promyelocytic leukemia presenting CD56 antigen expression treated with the pethema LPA99 trial. Haematologica Reports. 2005;1:86;(abstract C20)
  12. Gallagher RE, Lee SJ, Sankoorikal B-J, et al. Independent prognostic significant of FLT3 internal tandem duplication (ITD) mutations in acute promyelocytic leukemia (APL) patients treated on ECOG protocol E2491. Blood. 2002;100:326a;(abstract)
  13. Shih LY, Kuo MC, Liang DC, et al. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer. 2003;98:1206–1216
  14. Noguera NI, Breccia M, Divona M, et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia. 2002;16:2185–2189
  15. Slack JL, Willman CL, Andersen JW, et al. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129. Blood. 2000;95:398–403
  16. Ko BS, Tang JL, Chen YC, et al. Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia–the occurrence of retinoic acid syndrome is a risk factor. Leukemia. 1999;13:1406–1408
  17. Breccia M, Carmosino I, Diverio D, et al. Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count. British Journal of Haematology. 2003;120:266–270
  18. de Botton S, Sanz MA, Chevret S, et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia. 2006;20:35–41
  19. Breccia M, Petti MC, Testi AM, et al. Ear involvement in acute promyelocytic leukemia at relapse: a disease-associated ‘sanctuary’?. Leukemia. 2002;16:1127–1130
  20. Tallman MS. Strategies for advanced APL: Long-term follow-up of arsenic therapy and new approaches. Haematologica Reports. 2005;1:23–24
  21. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. The New England Journal of Medicine. 1998;339:1341–1348
  22. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology. 2001;19:3852–3860
  23. Shen Y, Shen ZX, Yan H, et al. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia. 2001;15:735–741
  24. Lu DP, Qiu JY, Jiang B, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood. 2002;99:3136–3143
  25. Au WY, Kumana CR, Kou M, et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood. 2003;102:407–408
  26. Dombret H, Fenaux P, Soignet SL, et al. Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Seminars in Hematology. 2002;39:8–13
  27. Douer D, Ramezani L, Watkins K, et al. Durable molecular remission in two acute promyelocytic leukemia (APL) patients treated with arsenic trioxide at first molecular relapse. Blood. 2005;106:525a;(abstract)
  28. Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. Journal of Clinical Oncology. 2005;23:2396–2410
  29. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94:3315–3324
  30. Raffoux E, Rousselot P, Poupon J, et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. Journal of Clinical Oncology. 2003;21:2326–2334
  31. Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 2002;99:4343–4349
  32. Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 2004;104:1995–1999
  33. de Botton S, Fawaz A, Chevret S, et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. Journal of Clinical Oncology. 2005;23:120–126
  34. Capria S, Latagliata R, Avvisati G, et al. BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results. Bone Marrow Transplantation. 2005;36:83–84
  35. Sanz MA, Arcese W, de la Rubia J, et al. on the behalf of the Acute Leukemia Working party of EBMT Stem cell transplantation (SCT) for acute promyelocytic leukemia (APL) in the ATRA era: a survey of the European Blood and Marrow Transplantation Group. Blood. 2000;96:522a;(abstract)
  36. Capria S, Diverio D, Ribersani M, et al. Autologous stem cell transplantation following BAVC regimen can be a curative approach for APL patients in II molecular remission. Blood. 2003;102:740a;(abstract)
  37. Lo-Coco F, Romano A, Mengarelli A, et al. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia. 2003;17:1930–1933
  38. Gilliland DG, Griffin JD. Role of FLT3 in leukemia. Current Opinion in Hematology. 2002;9:274–281
  39. Sohal J, Phan VT, Chan PV, et al. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood. 2003;101:3188–3197
  40. Li SW, Tang D, Ahrens KP, et al. All-trans-retinoic acid induces CD52 expression in acute promyelocytic leukemia. Blood. 2003;101:1977–1980
  41. Kini AR, Peterson LA, Tallman MS, et al. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood. 2001;97:3919–3924
  42. Alimoghaddam K, Shariftabrizi A, Tavangar SM, et al. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia. Leukemia & Lymphoma. 2006;47:81–88
  43. No authors listed . Erratum. Leukemia & Lymphoma. 2006;47:777
  44. Bachleitner-Hofmann T, Kees M, Gisslinger H. Arsenic trioxide: acute promyelocytic leukemia and beyond. Leukemia & Lymphoma. 2002;43:1535–1540
  45. Lin RJ, Nagy L, Inoue S, et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998;391:811–814
  46. Moon DO, Jin CY, Lee JD, et al. Curcumin decreases binding of Shiga-like toxin-1B on human intestinal epithelial cell line HT29 stimulated with TNF-alpha and IL-1beta: suppression of p38, JNK and NF-kappaB p65 as potential targets. Biological & Pharmaceutical Bulletin. 2006;29:1470–1475
  47. Thomas RK, Sos ML, Zander T, et al. Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies. Clinical Cancer Research. 2005;11:8186–8194
  48. Hussain AR, Siraj AK, Manogaran PS, et al. Curcumin induces apoptosis by inhibiting the expression of IAPs in human precursor B-acute lymphoblastic leukemic (PreB-ALL) cells. Blood. 2005;106:259a;(abstract)
  49. Kini AR, Nagabhushan M, Tallman MS, et al. Curcumin enhances differentiation of all-trans retinoic acid (ATRA)-sensitive and ATRA-resistant acute promyelocytic (APL) cells. Blood. 2005;106:192b;(abstract)
  50. Zhang P. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. Journal of Biological Regulators and Homeostatic Agents. 1999;13:195–200
  51. Ohnishi K, Yoshida H, Shigeno K, et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia. 2002;16:617–622
  52. Lazo G, Kantarjian H, Estey E, et al. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M.D. Anderson experience. Cancer. 2003;97:2218–2224

PII: S1521-6926(06)00083-1

doi: 10.1016/j.beha.2006.11.002

Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 57-65 , March 2007

Article Tools

* Image Usage & Resolution